• Transthera Sciences’ tinengotinib won conditional NMPA approval on Aug. 6, 2026 for FGFR2 fusion/rearrangement cholangiocarcinoma post systemic therapy, FGFR inhibitor.
• Drug is positioned as the first approved option in China for patients relapsing or resistant to prior FGFR inhibitor therapy.
• Global multi-center Phase III cholangiocarcinoma trial finished planned enrollment, supporting overseas registration filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences (Nanjing) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300312), on August 26, 2026, and is solely responsible for the information contained therein.